https://aethontx.com/new-biotechnology-combines-targeted-and-immune-therapies-to-kill-treatment-resistant-cancer-cells/2023-01-09T11:28:02+00:00https://aethontx.com/atp-and-nyu-langone-health-launch-aethon-therapeutics-to-eradicate-drug-resistant-cancer-cells/2023-01-09T11:56:57+00:00https://aethontx.com/national-cancer-institute-cancer-currents-blog-can-targeted-therapy-for-kras-mutations-double-as-part-of-immunotherapy/2023-01-09T11:27:55+00:00https://aethontx.com/aethon-therapeutics-announces-collaboration-with-revolution-medicines-to-discover-and-develop-novel-aethon-antibody-programs/2024-04-04T12:08:54+01:00https://aethontx.com/aethon-therapeutics-to-share-preclinical-and-discovery-stage-updates-on-kras-g12c-hapten-peptide-immunotherapies-at-aacr-2025/2025-12-19T17:50:44+00:00https://aethontx.com/new-publication-in-nature-communications-demonstrates-the-therapeutic-utility-of-targeting-synthetic-neoantigens-generated-by-krasg12c-inhibitors/2025-12-19T17:51:06+00:00